Tumor Biology

, Volume 35, Issue 8, pp 7713–7717 | Cite as

RETRACTED ARTICLE: Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer

  • Ling Liu
  • Jing Zou
  • Qi Wang
  • Fu-Qiang Yin
  • Wei Zhang
  • Li Li
Research Article

Abstract

The aim of this study is to examine the microRNA (miRNA) expression of epithelial ovarian cancer (EOC) in both drug-resistant and drug-sensitive tissues and to explore the pathogenic characteristics of drug-resistant miRNAs in EOC. The samples with 10 cases of drug-resistant and drug-sensitive EOC tissue were obtained from undergoing surgical resection of ovarian cancer (OC). Total miRNAs were extracted and isolated, respectively. Hybridization was carried out on miRNA microarray chip. Real-time polymerase chain reaction (RT-PCR) was performed to confirm the difference of miRNA expression. Bioinformatic software was used to predict the possible target genes of each miRNA which expressed differently. The results indicated that four miRNAs related drug-resistance been identified, and the expression of hsa-miR-152 and hsa-miR-381 in drug-resistant OC tissue was significantly higher compared with those in drug-sensitive tissue (P < 0.01). However, expression of hsa-miR-200a-3p and hsa-miR-429 were downregulated in drug-resistant tissues (P < 0.01). The results obtained by miRNA microarrays of differential expression with hsa-miR-106b-3p, hsa-miR-152, hsa-miR-200a-3p, hsa-miR-381, and hsa-miR-429 were confirmed by real-time PCR. There were 62 significantly different miRNAs, including 42 significant upregulated miRNAs and 20 significant downregulated miRNAs in the drug-resistant tissue. Five databases, including Target Scan, miRanda, miRDB, PicTar5, and RNA22, were used for bioinformatics prediction. In conclusion, miRNA microarray analysis has become a fast and efficient molecular biological technology for the study of biological information. hsa-miR-152, hsa-miR-200a-3p, hsa-miR-381, and hsa-miR-429 may participate in the formation of drug resistance in EOC through the target genes predicted.

Keywords

Epithelial ovarian cancer Drug-resistant tissues and drug-sensitive tissues MicroRNA microarray chip Real-time PCR 

Notes

Acknowledgements

This study was supported by National High Technology Research and Development Program of China (No. 012AA02A507), and the Research Fund for the Doctoral Program of Higher Education of China (No. 20134503110009).

Conflicts of interest

None

References

  1. 1.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.CrossRefPubMedGoogle Scholar
  2. 2.
    Samrao D, Wang D, Ough F, Lin YG, Liu S, Menesses T, et al. Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy. Transl Oncol. 2012;5(6):469–74.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Matsuo K, Eno ML, Im DD, Rosenshein NB, Sood AK. Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol. 2010;116(1):61–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Ying H, Lv J, Ying T, Yang Q, Ma Y. microRNA and transcription factor mediated regulatory network for ovarian cancer. Tumor Biol. 2013;34(5):3219–25.CrossRefGoogle Scholar
  5. 5.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.CrossRefPubMedGoogle Scholar
  6. 6.
    Zimmerman AL, Wu S. MicroRNAs, cancer and cancer stem cells. Cancer Lett. 2011;300(1):10–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006;94(6):776–80.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini G. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008;111(3):478–86.CrossRefPubMedGoogle Scholar
  9. 9.
    Kim YW, Kim EY, Jeon D, Liu JL, Kim HS, Choi JW, et al. Differential microDNA expression signatures and cells type-specific associated with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther. 2014;8(1):293–314.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Raza U, Zhang JD, Sahin O. MicroRNA expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res. 2014;20(7):1990–2000.CrossRefGoogle Scholar
  11. 11.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20(2):207–25.CrossRefPubMedGoogle Scholar
  13. 13.
    Yu X, Zhang X, Bi T, Ding Y, Zhao J, Wang C, et al. miRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. Tumor Biol. 2013;34(6):3501–8.CrossRefGoogle Scholar
  14. 14.
    Hassan MK, Watari H, Christenson L, Bettuzzi S, Sakuragi N. Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel. Tumor Biol. 2011;32(5):1031–47.CrossRefGoogle Scholar
  15. 15.
    Burchenal JH, Robinson E, Johnston SF, Kushida MN. The induction of resistance to 4-amino-N10-methylpteroylglutamic acid in a strain of transmitted mouse leukemia. Science. 1950;111(2875):116.CrossRefPubMedGoogle Scholar
  16. 16.
    Boren T, Xiong Y, Hakam A, Wwnham R, Apte S, Chan G, et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 2009;113(2):249–55.CrossRefPubMedGoogle Scholar
  17. 17.
    Ying H, Lv J, Ying T, Li J, Yang Q, Ma Y. microRNA and transcription factor mediated regulatory network for ovarian cancer. Tumor Biol. 2013;34(5):3219–25.CrossRefGoogle Scholar
  18. 18.
    Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, et al. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther. 2012;11(12):2556–65.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sun C, Li N, Zhou B, Yang Z, Ding D, Weng D, et al. miR-222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27kip1. Oncol Lett. 2013;6(2):507–12.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Li H, Xu H, Shen H, Li H. microRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells. Oncol Lett. 2014;7(1):7183–8.Google Scholar
  21. 21.
    Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug resistant ovarian cancer cells. Gynecol Oncol. 2008;111(3):478–86.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Ling Liu
    • 1
  • Jing Zou
    • 1
  • Qi Wang
    • 1
  • Fu-Qiang Yin
    • 2
  • Wei Zhang
    • 1
  • Li Li
    • 1
  1. 1.Department of Gynecology Oncology, Affiliated Tumor HospitalGuangxi Medical UniversityNanningChina
  2. 2.Medical Scientific Research CenterGuangxi Medical UniversityNanningChina

Personalised recommendations